BeOne Medicines Ltd.

ONC · Nasdaq · SIC 2834: Pharmaceutical Preparations · Market Cap: $33.1B · 12,000 employees
306
SEC Filings
$287.92
Close 2026-05-29
2
Transcripts
12,000
Employees

Business Summary

BeOne Medicines Ltd. (formerly BeiGene) is a global oncology company focused on developing and commercializing innovative medicines for cancer patients. The company develops both small molecule and large molecule biologic therapies, operates its own manufacturing facilities, and markets approved medicines across the U.S., China, EU, UK, Switzerland, and other international markets. It also engages in strategic collaborations and licensing arrangements to expand its pipeline.

Latest Stock Quote

ONC 2026-05-29 $287.92 O:$293.3 H:$294.3 L:$287.53 Vol:0.2M VWAP:$289.7086
origin leaf: 90ee1f12924051648768ed8588407b55d47ff686747f94e81e5b3aff357e94c0

Next Earnings

Q2 FY2026 — expected 2026-08-19

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionONCdiscussed RegulationQ4 FY2025
topic_mentionONCdiscussed AutomotiveQ4 FY2025
topic_mentionONCdiscussed Healthcare & BioQ4 FY2025
guidanceONCguided guidance of $6.2 billionQ4 FY2025
guidanceONCguided guidance for full year 2026 of $6.2 billionQ4 FY2025
guidanceONCguided guidance on items impacting net income and earnings per ADS: • Other income (expense) : estimated range of $25 millionQ4 FY2025
topic_mentionONCdiscussed Artificial Intelligence
topic_mentionONCdiscussed Blockchain & Crypto
topic_mentionONCdiscussed Networking
topic_mentionONCdiscussed Regulation
topic_mentionONCdiscussed Automotive
topic_mentionONCdiscussed Healthcare & Bio
metricONC free cash flowreported $380 million
guidanceONCguided expected to be between $700 and $800 million
guidanceONCguided expect expenses to be between $25 to $50 million
outlookONCstated we believe that true innovation comes from improving upon the best
outlookONCstated We believe BeOne is the only company with the foundational assets in our CLL portfolio and pipeline to take us there
outlookONCstated we believe ZS is that therapy
outlookONCstated We expect another strong year of revenue growth with continued global leadership for BRUKINSA
outlookONCstated We anticipate that the U

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-262025-12-310001628280-26-011946EDGAR136K words
2025-02-272024-12-310001651308-25-000031EDGAR—
2024-02-262023-12-310001651308-24-000014EDGAR—
2023-02-272022-12-310001651308-23-000036EDGAR—
2022-02-282021-12-310001651308-22-000032EDGAR—
2021-02-252020-12-310001651308-21-000039EDGAR—
2020-03-022019-12-310001651308-20-000020EDGAR—
2019-02-282018-12-310001651308-19-000018EDGAR—
2018-02-282017-12-310001558370-18-001303EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-05-062026-03-310001628280-26-030867EDGAR—
2025-11-062025-09-300001628280-25-049824EDGAR71K words
2025-08-062025-06-300001651308-25-000133EDGAR—
2025-05-072025-03-310001651308-25-000075EDGAR—
2024-11-122024-09-300001651308-24-000152EDGAR—
2024-08-072024-06-300001651308-24-000098EDGAR—
2024-05-082024-03-310001651308-24-000051EDGAR—
2023-11-092023-09-300001651308-23-000165EDGAR—
2023-08-022023-06-300001651308-23-000127EDGAR—
2023-05-042023-03-310001651308-23-000068EDGAR—
2022-11-092022-09-300001651308-22-000209EDGAR—
2022-08-082022-06-300001651308-22-000139EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-05-150001651308-26-000012EDGAR—
2026-05-060001628280-26-030866EDGAR—
2026-04-140001651308-26-000008EDGAR1K words
2026-02-260001628280-26-011941EDGAR8K words
2025-12-190001651308-25-000153EDGAR—
2025-12-180001651308-25-000151EDGAR—
2025-11-190001651308-25-000148EDGAR—
2025-11-060001628280-25-049821EDGAR—
2025-08-290001651308-25-000136EDGAR—
2025-08-250001628280-25-041082EDGAR—

306 total filings indexed. 275 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Earnings Transcripts

Call DateQuarterTitle
—Q4 FY2025ONC Q4 FY2025 Earnings Call Transcript
— ONC Earnings Call Transcript

Access full transcripts via API (JSON) — includes speakers, key metrics, competitive mentions, and origin provenance chain.

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

oncology united-states china european-union united-kingdom switzerland international-markets

Company Identity

CIK0001651308
TickerONC
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
Websitehttps://www.beonemedicines.com
Listed2016-02-03

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: a5f7caf643c01b3c1ee0784b19e6d3edadc887db269e638c487e273f732caa4b
parent: dcca8a7fb28eb1b9488046f3bdce6e9b8b0bf842c712f1506002817017724fba
content hash: c9c967d7bc1ff32ba960d4d541a4048a017b283b0aa0fcd0e59ebe01404599fe
signed: 2026-06-02T19:02:10.484Z
sources: 24 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf